Hospital Regional Universitario de Málaga
Málaga, MALAGA, 29009, Spain
NCT Number: NCT05184738
Anorexia nervosa causes gastroparesis, constipation, and can lead to elevated liver enzymes. It is often necessary to supplement the diet of patients with nutritional formulas. The ingestion of a peptide formula, with partially hydrolyzed protein and rich in medium chain triglycerides, could favor its digestion and absorption, improving its tolerance and acceptance by the patient, compared to a polymeric formula.
Looking for future studies?
Notify Me12 year–40 year
All sexes
Interventional
Not applicable
Málaga, MALAGA, 29009, Spain
Main objective:
Secondary Objectives:
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Intervention group will receive a oligomeric nutritional formula (Bi1 peptidic Adventia Pharma, Spain).
Standard nutritional formula (isocaloric and isoprotein compared to the experimental treatment).
Time frame: From baseline to week 1
Differences in the score of the questionnaire: "Evaluation questionnaire for gastrointestinal complaints". This questionnaire assesses the presence (and where appropriate its degree) or absence of nausea, vomiting, diarrhea, constipation, reflux or heartburn. Each section has a score from 0 to 10, which will be filled in by the patient himself.
Time frame: From baseline to week 1 in group 1; from baseline to week 8 in group 2
Difference in score in the questionnaire "Evaluation questionnaire for gastrointestinal complaints". This questionnaire assesses the presence (and where appropriate its degree) or absence of nausea, vomiting, diarrhea, constipation, reflux or heartburn. Each section has a score from 0 to 10, which will be filled in by the patient himself.
Time frame: From baseline to week 1 in group 1; from baseline to week 8 in group 2
Change in the score of the "Product sensory evaluation questionnaire". It consists of 11 items, which assess how the patient perceives the organoleptic characteristics of the product and their satisfaction after taking it. Each item consists of a score from 0 to 10 that the patient has to fill in. The items can refer to positive or negative characteristics of the product, so the level of score in each of them can indicate better or worse characteristics of the product depending on the characteristic in question.
Time frame: From baseline to week 8 in group 2
Adherence will be determined by daily registration of the percentage they take of the supplement.
Time frame: From baseline to week 8 in group 2
Dietary registration of natural food intake at breakfast, mid-morning snack and lunch, in group 2 patients. It will be done through the DIETSTAT program. The total amount of calories and the percentage of macronutrients will be determined.
Time frame: From baseline to week 8
Weight will be measured in kg
Time frame: From baselilne to week 8
It will be determined with a JAMAR dynamometer. The mean and maximum of three measurements made on the dominant hand and the mean and maximum of three measurements made on the non-dominant hand will be taken. The outside will be measured in kg.
Time frame: From baselilne to week 8
Determined by AKERN bioimpedance analyzer and measured in kg
Time frame: From baselilne to week 8
Determined by AKERN bioimpedance meter and measured in kg
Time frame: From baselilne to week 8
Determined by AKERN bioimpedance analyzer and measured in l
Time frame: From baselilne to week 8
Determined by AKERN bioimpedance analyzer and measured in l
Time frame: From baselilne to week 8
Determined by AKERN bioimpedance analyzer and measured in degrees of angle
Time frame: From baselilne to week 8
Determined by AKERN bioimpedance analyzer and measured in kg
Time frame: From baselilne to week 8
Changes in the score of the "SF-12 Health Questionnaire" questionnaire. This questionnaire is the adaptation made for Spain of the SF-12 Health Survey. The SF-12 is a shortened version of the SF-36 Health Questionnaire designed for uses where it is too long. Provides a health status profile. It consists of 12 items from the 8 dimensions of the SF-36 Physical Function (2), Social Function (1), Physical role (2), Emotional role (2), Mental health (2), Vitality (1), Body pain (1), General Health (1). The response options form Likert-type scales that assess intensity or frequency. The number of answer options ranges from three to six, depending on the item. For each of the 8 dimensions, the items are coded, added and transformed on a scale that ranges from 0 (the worst health status for that dimension) to 100 (the best health status).
Time frame: From baselilne to week 8
Changes in the score of the "Eating Disorder Examination-Q (EDE-Q)" test. This questionnaire takes about 10 minutes to complete. It studies the scope and severity of the characteristics associated with the diagnosis of eating disorder. It includes 4 subscales: Restriction-diet, Preoccupation with food, Preoccupation with weight and Concern about the figure. Includes a definition of the term "binge" (eg, "episodes in which you have eaten an abnormally large amount of food under the circumstances" and experiencing a "loss of control" over eating). The EDE-Q generates two types of data: frequency data on key behavioral features of eating disorders in terms of number of episodes of the behavior, and subscale scores reflecting the severity of characteristics of eating disorders. Higher scores on the global scale and subscales denote more problematic eating behaviors and attitudes.
Time frame: From baseline to week 8
Changes in the score of the "Hospital Anxiety and Depression Scale (HADS)". This aims to detect depressive and anxiety disorders in non-psychiatric hospital services, avoiding overlap with symptoms due to physical illness, without taking into account the physical aspects that may accompany anxiety / depression, only affecting the emotional ones. It is a self-administered scale with 14 items divided into 2 subscales (anxiety and depression) whose maximum score is 21 points for each of them. Based on the score obtained, patients can be classified as normal (<7), doubtful (between 8 and 10) and potential clinical case (≥ 11). The score is referred to the last week.
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
Other
Evaluation of the Tolerance of Two Oral Nutritional Supplements in Patients with Anorexia Nervosa
Acronym: PEPTIDICAN21
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05913557
Anorexia Nervosa, Anxiety Disorders
St Louis, Missouri, United States
View Trial DetailsNCT01121211
Anorexia Nervosa, Anxiety
Boston, Massachusetts, United States
View Trial DetailsNCT06736769
Anorexia, Anorexia Nervosa
San Francisco, California, United States
View Trial DetailsNCT04806620
ARFID, Ankylosing Spondylitis (AS)
Delafield, Wisconsin, United States
View Trial Details